(1)
Ultimovacs ASA ( Ultimovacs ) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced the publication in
Frontiers in Immunology of its positive long-term Overall Survival (OS) data from the Phase I trial evaluating the Company s universal cancer vaccine, UV1, in combination with checkpoint inhibitor ipilimumab in patients with metastatic malignant melanoma. As published in the journal, in addition to the achievement of the primary endpoints of safety and tolerability, 50% of the patients were still alive at the data cut-off, supporting the combination of the Company s proprietary UV1 vaccine with ipilimumab, a CTLA-4 checkpoint inhibitor and standard-of-care treatment, in this late-stage patient population.
Fatigue Prevalence Remains High in MS Patients multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
OSLO, Norway, May 10, 2021 /PRNewswire/ Hemispherian AS ( Hemispherian or the Company ), an innovative Norwegian preclinical pharmaceutical company focused on epigenetic therapeutics for the treatment of cancer, is delighted to announce the formation of its Clinical Advisory Board (CAB) by appointing as Chairman Dr Roger Stupp, Chief of Neuro-Oncology in the Department of Neurology and Paul C Bucy Professor of Neurological Surgery at Northwestern University Chicago and as members Dr. Michael Lim, Chairman of the Department of Neurosurgery at Stanford University; Dr. Monika Hegi Head of the Laboratory of Brain Tumour Biology and Genetics at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne; and Dr. Einar O. Vik-Mo, Head of the Surgical Neuro-Oncology section at Oslo University Hospital. The advisory board – comprising leading experts in their fields and having significant experience with novel technologies and their translat
Higher education does not influence brain ageing
A new study from the Lifebrain consortium, coordinated by the University of Oslo with the participation of the University of Barcelona, finds that higher education does not slow brain ageing, contrary to the popular belief. This study has been published in the journal
Proceedings of the National Academy of Sciences.
Researchers have known for a long time that all brains shrink with age. A common perception has been that education would be a way to hold back this shrinkage. However, there is no evidence to prove this hypothesis.
One of the participants in this study, David Bartrés Faz, expert from the Institute of Neurosciences of the UB (UBNeuro), notes that “a positive association between the level of education and the level of neurocognitive functioning has been reported in some past studies, and it is consistent with the idea that individuals with higher education have an initial advantage over individuals with lower educa
Higher education does not influence brain ageing
10/05/2021
A new study from the Lifebrain consortium, coordinated by the University of Oslo with the participation of the University of Barcelona, finds that higher education does not slow brain ageing, contrary to the popular belief. This study has been published in the journal
Proceedings of the National Academy of Sciences.
Researchers have known for a long time that all brains shrink with age. A common perception has been that education would be a way to hold back this shrinkage. However, there is no evidence to prove this hypothesis.
One of the participants in this study, David Bartrés Faz, expert from the Institute of Neurosciences of the UB (UBNeuro), notes that “a positive association between the level of education and the level of neurocognitive functioning has been reported in some past studies, and it is consistent with the idea that individuals with higher education have an initial advantage over in